Ironwood Pharmaceuticals (IRWD) Non-Current Debt (2013 - 2026)

Ironwood Pharmaceuticals (IRWD) has 11 years of Non-Current Debt data on file, last reported at $385.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt changed 0.0% year-over-year to $385.0 million; the trailing twelve-month figure through Mar 2026 stood at $385.0 million (changed 0.0% YoY), and the FY2025 full-year result was $385.0 million, changed 0.0% from the prior year.
• Non-Current Debt was little changed at $385.0 million in Q1 2026, from $385.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $425.0 million in Q2 2024 to a low of $275.0 million in Q1 2024.
• A 4-year average of $369.6 million and a median of $385.0 million in 2024 frame the typical range for Non-Current Debt.
• Peak annual rise in Non-Current Debt reached 40.0% in 2025, while the deepest fall reached 9.41% in 2025.
• Tracing IRWD's Non-Current Debt over 4 years: stood at $300.0 million in 2023, then increased by 28.33% to $385.0 million in 2024, then changed by 0.0% to $385.0 million in 2025, then changed by 0.0% to $385.0 million in 2026.
• Business Quant data shows IRWD's Non-Current Debt at $385.0 million in Q1 2026, $385.0 million in Q4 2025, and $385.0 million in Q3 2025.